Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,779
datasets available to search
ShareScore release 0.9.0
Dataset results
1,779 results for “Hodgkin lymphoma”
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT03892421. IPD Sharing: NO. Countries: 1. Publications: 4.
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
ClinicalTrials.gov study NCT00179660. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
ClinicalTrials.gov study NCT07225439. IPD Sharing: NO. Countries: 1. Publications: 11.
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
ClinicalTrials.gov study NCT03729609. IPD Sharing: YES. Countries: 1. Publications: 0.
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT04094142. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT03533283. IPD Sharing: YES. Countries: 6. Publications: 1.
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
ClinicalTrials.gov study NCT03033914. IPD Sharing: Not stated. Countries: 2. Publications: 1.
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
ClinicalTrials.gov study NCT04089215. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
ClinicalTrials.gov study NCT05675410. IPD Sharing: YES. Countries: 3. Publications: 1.
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
ClinicalTrials.gov study NCT01329354. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
ClinicalTrials.gov study NCT02815137. IPD Sharing: NO. Countries: 1. Publications: 1.
Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes
ClinicalTrials.gov study NCT01304849. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
ClinicalTrials.gov study NCT01567709. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT01815749. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00040950. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
ClinicalTrials.gov study NCT04233294. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
ClinicalTrials.gov study NCT01421524. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00278421. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
ClinicalTrials.gov study NCT03722147. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
ClinicalTrials.gov study NCT03655483. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.